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ABSTRACT: An eﬃcient method is reported, for the fabrication of
composite microﬁbers that can be magnetically actuated and are
biocompatible, targeting controlled drug release. Aqueous solutions of
polyvinyl alcohol, incorporated with citric acid-coated Fe3O4 magnetic
nanoparticles (MNPs), are subject to infusion gyration to generate 100−
300 nm diameter composite ﬁbers, with controllable MNP loading. The
ﬁbers are stable in polar solvents, such as ethanol, and do not show any
leaching of MNPs for over 4 weeks. Using acetaminophen as an example,
we demonstrate that this material is eﬀective in immobilization and
triggered release of drugs, which is achieved by a moving external
magnetic ﬁeld. The remote actuation ability, coupled with biocompat-
ibility and lightweight property, renders enormous potential for these
ﬁbers to be used as a smart drug release agent.
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1. INTRODUCTION
Magnetically triggered release of active pharmaceutical
ingredients is a rapidly growing area of research with
applications targeted toward eﬃcient, minimally invasive
pathways of drug delivery.1−4 Such studies usually involve the
use of superparamagnetic nanoparticles, which are either
functionalized as drug-carriers5,6 or incorporated with polymers
to produce composites in the form of membranes,7 lip-
osomes,8−10 protein microspheres,3 gels,11 etc. These materials
have become highly signiﬁcant in the advancement of diagnosis
and treatment of cancer and cardiovascular diseases, in addition
to leading toward breakthroughs in regenerative medicine.12−16
The magnetic component is typically activated via hyper-
thermia or chemical signals to trigger the release of the
drug.17,18 Actuation of the drug-carrying platform by an
external magnetic ﬁeld (i.e., magnetic actuation), however,
remains scarcely explored but has enormous potential in
biomedicine.19,20 Such systems can potentially lead to remote-
controlled, precise, and safer pathways of drug delivery and also
pave the way for advances in the rapidly evolving ﬁeld of
microrobotics and for applications in medicine.20−22
Recent reports indicate that in vitro drug release, in
particular, can be improved using conventional carrier systems
such as mesoporous silica, in combination with magnetic
nanoparticles (MNPs) for triggered cargo release.23−25 Such
systems have great potential for the treatment of cancer and
other related diseases.26 These systems, however, need physical
(e.g., thermal or light) or chemical (e.g., pH or redox changes)
stimuli or enzymatic catalysis to initiate the release action,
which require either invasive procedures or are limited in
eﬃciency and controllability. In contrast, systems containing
MNPs give rapid responses, with greater noninvasiveness, and
can be easily controlled by external magnetic ﬁelds. MNPs also
have the advantage of being easily integrated with organic
components such as polymers to create composite materials
with novel and improved capabilities.12
Polymer-based nanoﬁbers have been investigated for a
myriad of biomedical applications, including scaﬀolds for tissue
engineering, materials for wound dressing, and vehicles for drug
delivery.27 Nanoscale ﬁbers are of particular interest in
biomedicine, as their morphology resembles biological tissue.
They also have high surface area and surface energy and can be
organized into porous hierarchical structures, which are highly
desirable properties for cell and tissue adhesion as well as the
adsorption of drug molecules. The physical structure of the
ﬁbers can be readily customized to adapt to diﬀerent
applications. In such instances, synthesis is mostly achieved
via electrospinning.28−30 This technique has been explored
extensively to achieve hollow core−shell microparticle-
encapsulated ﬁbers.31 Furthermore, materials used for ﬁber
formation have been developed to facilitate the incorporation of
ﬁbers with biodegradable32,33 and antibiotic properties34 and
even those that include living tissue.35−37 Extensive progress
Received: March 23, 2018
Accepted: April 12, 2018
Published: April 12, 2018
Research Article
www.acsami.orgCite This: ACS Appl. Mater. Interfaces 2018, 10, 15524−15531
© 2018 American Chemical Society 15524 DOI: 10.1021/acsami.8b04774
ACS Appl. Mater. Interfaces 2018, 10, 15524−15531
This is an open access article published under a Creative Commons Attribution (CC-BY)
License, which permits unrestricted use, distribution and reproduction in any medium,
provided the author and source are cited.
D
ow
nl
oa
de
d 
vi
a 
K
IN
G
ST
O
N
 U
N
IV
 o
n 
M
ar
ch
 9
, 2
02
0 
at
 1
6:
23
:1
1 
(U
TC
).
Se
e 
ht
tp
s:/
/p
ub
s.a
cs
.o
rg
/sh
ar
in
gg
ui
de
lin
es
 fo
r o
pt
io
ns
 o
n 
ho
w
 to
 le
gi
tim
at
el
y 
sh
ar
e 
pu
bl
ish
ed
 a
rti
cl
es
.
has also been made in the scale-up of such materials targeting
industrial applications.38
Despite the wealth of research conducted, such nanoﬁbers
have not yet, however, made it to the clinical trial stage of
biomedical applications. This can be attributed to multiple
factors, from mass production to long-term stability of the
ﬁbers in vivo. For example, electrospinning, which is the main
synthesis method of ﬁber formation, poses many challenges to
their sustained usage in medical applications. The lack of
control over ﬁber diameter and pore sizes, as well as the
random nonwoven nature of the ﬁbers produced, causes
diﬃculty in cell penetration, which is a key factor in sustained
use of scaﬀolds for tissue engineering.39,40 Although electro-
spinning is eﬀective in producing microscale ﬁbers, smaller
diameters are diﬃcult to obtain.41 Attempts at customizing ﬁber
morphology via this technique are complicated and lead to
lower yields.42 Moreover, electrospun ﬁbers have inherently
weaker mechanical strength than cast ﬁbers, and the solvents
and cross-linking agents involved in the process often lead to
toxicity and noncompatibility in biological systems.43
Alternative spinning techniques have been developed to
counteract some of the drawbacks of electrospinning.44 These,
however, are not without ﬂaws themselves. Biospinning, for
example, is a technique suitable for producing ﬁbers with
greater mechanical strength, such as scaﬀolds for tendons or
bones.45 Nevertheless, this method is hampered by high cost,
diﬃculty in scale-up, longer production times, and lack of
customizability. Melt spinning can create ﬁbers by extruding a
heated polymer through a spinneret with textural control for
cell applications.46,47 Yet, high energy costs, expensive equip-
ment, and diﬃculty in producing cell-incorporating ﬁbers are
considerable impediments. The latter issue can be solved via an
interfacial complexation process, to encapsulate cells, which is
also cheaper;48 despite this, limitations in scale-up and material
and dimension control are signiﬁcant disadvantages. Overall, a
technique to produce such biocompatible ﬁbers in a facile, fast,
and cost-eﬀective manner, with controllable sizes and the
potential for scale-up, is highly desirable. If the above is also
coupled with the ability of remote actuation, it can lead to
signiﬁcant advancements in drug delivery and tissue engineer-
ing.
The goal of this study is to demonstrate a magnetically
actuated drug delivery system, based on polyvinyl alcohol
(PVA)−MNP ﬁbers, generated via infusion gyration. The ﬁbers
are made of biocompatible components in order to target
biomedical applications, speciﬁcally drug release. The ability of
these ﬁbers to be actuated via an external magnetic ﬁeld is
demonstrated, along with extensive characterization of their
physicochemical properties. The release of controlled quantities
of acetaminophen, via magnetic actuation of this material, is
explored. Furthermore, the advantages and potential scope of
application, beyond drug delivery, are discussed.
2. EXPERIMENTAL SECTION
All reagents and chemicals were used as received, without further
modiﬁcation.
2.1. Preparation of PVA and PVA−MNP Solutions. Three
types of PVA polymer powder (Sigma-Aldrich, Gillingham, UK), with
diﬀerent molecular weights, were taken in the following weight ratios
to obtain three viscous solutions (Table 1): (1) PVA (363 170, 87−
89% hydrolyzed), (2) PVA (363 138, 98−99% hydrolyzed), (3) PVA
(363 065, 99+% hydrolyzed). The three solutions were made by
mixing in the relevant weight of each type of PVA powder with
distilled water and heating under magnetic stirring at 90 °C, for 5 h, to
achieve homogeneous mixtures.
Next, the three solutions were mixed in a volume ratio of 1:1:1, to
make a total of 30 mL and magnetically stirred at ambient temperature
(23 °C) for 24 h. This mixture was stored in sealed glass vials until use.
All ﬁber samples used in this study consisted of the above mixture.
Subsequently, this solution was mixed with 5% (w/w) Fe3O4 magnetic
nanopowder (∼20 nm), coated with citric acid (see section 2.2 below),
and vigorously vortexed for 5 min to obtain PVA−MNP solutions.
Both the pure PVA and PVA−MNP solutions were then spun into
ﬁbers, according to the procedures described in section 2.3.
2.2. Citric Acid Coating of MNPs. MNPs were subject to acid
coating prior to mixing with PVA, in order to ensure eﬀective
dispersion in the aqueous polymer solution. Citric acid (Sigma-
Aldrich, ACS grade >99.8%) was dissolved in deionized water in a
ratio of 0.5 mg/mL, at 90 °C for 1 h, under magnetic stirring. Then,
the stirrer was removed, and a relevant weight of Fe3O4 MNPs (US
Research Nanomaterials, Inc., 20 nm) was added to the solution and
mixed for another 1 h. Afterward, the acid-coated MNPs were
precipitated by placing a magnet under the bottom of the vessel, and
the solution was decanted. The collected MNPs were then washed
twice, with 100 mL of deionized water, and dried at 80 °C in an oven,
for 3 h or until a constant weight was obtained.
2.3. Fabrication of Fibers. The ﬁbers were fabricated using a
previously reported49 in-house built experimental setup, using the
principle of infusion gyration (Figure 1; also see Supporting
Information Video S1). The device consists of a hollow aluminum
rotary vessel, 25 mm in height and 60 mm in diameter, and contains
20 small round oriﬁces. Each oriﬁce is of 0.5 mm in diameter and lies
along the central circumference of the cylindrical vessel. The vessel is
connected to and powered by a dc motor and a speed controller,
which can provide variable speeds of rotation. The rotational speed
was ﬁxed at 36 000 rpm for this study. The top of the vessel contains a
removable cap, with a rotary joint connected to a lead. The other tip of
the lead is connected to a syringe pump (PHD 4400 Programmable
Syringe Pump, Harvard Apparatus). The ﬂow rate of the solution to
the vessel is tuned via the syringe pump and was held at 4 mL/min
during this study. A stationary steel mesh was placed 120 mm away
from the rotating vessel to help collect the ﬁbers. The solutions
consisting of either PVA or MNPs containing PVA were spun at
ambient conditions of 23 °C and ∼40% relative humidity. After the
Table 1. Molecular Weights and Weight Ratios of PVA
Polymers Used for Pure PVA and PVA−MNP Fiber
Fabrication
PVA type molecular weight weight %
1 13 000−23 000 22
2 31 000−50 000 10
3 146 000−186 000 7
Figure 1. Making polymer-based ﬁbers via infusion gyration. (A)
Schematic diagram of the spinning process. (B) High-speed camera
image of the spinning cylinder showing ﬁber formation.
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spinning was completed, all samples were transferred to sealed
containers for further characterization.
2.4. Characterization of PVA and PVA−MNP Fibers. Fiber
samples were observed under a Nikon Eclipse ME 600 optical
microscope, ﬁtted with a MicroPublisher 3.3 RTV, 3.3 megapixel CCD
Color-Bayer Mosaic, Real Time Viewing camera (Media Cybernetics,
Marlow, UK). Size and morphology of the ﬁbers were analyzed using
ﬁeld emission scanning electron microscopy (FESEM) with a JEOL
JSM6310F instrument. All samples were coated with carbon prior to
imaging, using a Quorum K975X turbo-pumped thermal evaporator
(Quorum Technologies Ltd., East Sussex, UK). Chemical character-
ization was achieved via FTIR spectroscopy, with a Bruker VERTEX
70 instrument. An INCA X-sight EDAX system (Oxford Instruments)
was used with Hitachi S-3400N for EDX (energy-dispersive X-ray)
spectroscopy for surface elemental analysis. Stability of the composite
ﬁbers was studied by immersing in an absolute ethanol solution for 4
weeks, followed by testing for Fe3O4 leaching via UV−vis spectros-
copy, using an Agilent Technologies Cary 4000 UV−vis spectropho-
tometer.
2.5. Magnetic Actuation and Characterization. Magnetic
actuation of the MNP-containing ﬁbers was achieved using
commercial neodymium magnets (emagnets UK, EP336, 20 mm dia
× 5 mm, N42, NiCuNi plated, 1.4 T), in air and in ethanol. The ﬁbers
eﬀectively responded to the external magnetic ﬁeld while contained in
glass vials open to air or in glass vials containing absolute ethanol. The
ﬁbers could also easily be guided in a channel containing ethanol.
Magnetization measurements were performed using a Quantum
Design MPMS SQUID-VSM magnetometer. Samples were weighed
and mounted within polycarbonate holders and subsequently
measured (±1 T, 796 kA m−1, at 300 K).
2.6. Drug Release Experiments. Drug release experiments were
conducted in absolute ethanol medium, with acetaminophen (Sigma-
Aldrich, analytical standard) as a model drug. For each experiment, 5.0
mg of acetaminophen was transferred on to 60.0 mg of magnetic
ﬁbers. The ﬁbers were wetted with three drops of absolute ethanol,
prior to transfer of acetaminophen on to them. In order to ensure that
the drug was eﬀectively immobilized in the ﬁber network, the
acetaminophen powder was spread throughout and pressed against the
ﬁbers with a spatula. This system was then transferred to a glass vial
containing 10.0 mL of absolute ethanol. Both control experiments and
actuation experiments were conducted in duplicate, to measure the
release of acetaminophen into the solution with time. For the
actuation experiments, the ﬁber−drug system was continuously moved
via four stacked external magnets (see section 2.5). Samples of 500 μL
of the ethanol solute were taken out from the system, ﬁrst after every 1
min, up to 5 min, and then at every 5 min, for a total period of 30 min.
Subsequently, the samples were analyzed via UV−vis spectropho-
tometry, to determine the concentration of acetaminophen released
via magnetic actuation. The 500 μL taken out for sampling was
replaced with new ethanol each time, in order to keep a total constant
volume of 10 mL of ethanol throughout the experiment. The same
procedure was followed to conduct control experiments, with the
exception of the magnetic actuation.
The concentration of acetaminophen released into the solution was
measured via ultraviolet−visible (UV−vis) spectrophotometry at a
characteristic absorbance wavelength of 248 nm. UV−vis spectroscopy
was carried out using the absorbance mode of a BioTek Synergy H1
multidetection reader. These measurements were compared to a
calibration curve, and the acetaminophen concentrations of the
experimental samples were determined by the Beer−Lambert law.
3. RESULTS AND DISCUSSION
3.1. PVA and PVA−MNP Fibers via Infusion Gyration.
Spinning of polymer solutions through micro-oriﬁces under
high pressure and speed is a technique recently optimized to
mass-produce nanoﬁbers.49,50 This technology was extended to
include nanoparticles51 and protein52-containing polymer
solutions to generate composite ﬁbers. In the latter,52 the
ﬂow rate, rather than pressure, was controlled during gyration;
this is called infusion gyration. Here, this method was used to
successfully generate ﬁbers consisting of PVA polymer and
PVA−MNP.
The morphology of the ﬁbers was studied using optical and
scanning electron microscopies. Optical microscopy revealed a
ﬁber matrix containing small amounts of beads distributed in
the matrix, for both pure PVA (Supporting Information, Figure
S1A) and PVA−MNP (Figure 2A,B) samples. These beads
were observed to be hollow structures via SEM and could arise
from a combination of factors, such as the rheological
properties of the polymer solution together with the spinning
speed and pressure.53 Fibers made from both PVA and PVA−
MNP appeared to have a distribution of 100−300 nm in
diameter (Figure 2C,D and Supporting Information, Figure
S1B). The incorporation of Fe3O4 MNPs into the ﬁbers was
visualized via EDX dot mapping, which revealed that the iron
oxide powder was distributed homogeneously on the ﬁbers
(Figure 2E,F).
Chemical composition of the ﬁbers was analyzed using FTIR
and EDX. Examination of the FTIR peaks allowed the
identiﬁcation of all typical peaks for PVA and citric acid
(Figure 3A). These include the broad peaks at 3300 cm−1 from
the stretching mode of inter- and intramolecular hydrogen
bonds of O−H; 2920 and 2850 cm−1 from the C−H vibrational
mode of alkyl groups; 1735 cm−1 from the stretching mode of
CO of the carbonyl groups; 1085 cm−1 from the C−O−C
stretching mode; a shoulder at ∼1141 cm−1 from C−O
stretching of crystalline PVA; and 1242 cm−1 from the
symmetric stretching mode of citric acid.54−56
However, the characteristic vibrational bands of Fe3O4
usually found at 634, 582, and 397 cm−1, characteristic of
magnetite,57 were not discernible via the instrument used. The
presence of surface Fe was successfully detected using EDX and
was found to be in the range of 5−10% of atomic weight for
diﬀerent samples (Figure 3B,C).
In order to correctly quantify the amount of MNPs loaded
on to the ﬁbers, the material was subject to superconducting
quantum interference device (SQUID) analysis. It was found
that the ﬁbers were composed of 4.9% magnetic component by
weight (due to Fe3O4 MNPs), as determined by the fraction of
the mass magnetization for the PVA−MNP ﬁbers (M = 2.6 A
Figure 2. PVA−MNP ﬁbers (5% (w/w)). (A,B) Optical microscopy
images, (C,D) SEM images, and (E,F) SEM dot mapping: the red dots
indicate the presence of Fe in ﬁbers.
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m2 kg−1) and the pure MNPs (M = 53.8 A m2 kg−1) (Figure S3
and Figure 3D). Because the polymer solution fed to the
spinning apparatus consisted of 5% of MNPs by weight, this
shows that the process of infused gyration is highly eﬀective in
generating ﬁbers with minimal loss of the magnetic material.
This observation, coupled with the previously investigated
eﬃcacy of the gyration process,52 renders potential for scaled
up production of magnetic ﬁbers using this technique.
3.2. Controlled Release of Acetaminophen via
Magnetic Actuation of PVA−MNP Fibers. The ability to
release controlled quantities of drugs via application of an
external stimulus onto the carrier platform is a highly
advantageous feature for drug delivery. This was successfully
demonstrated by the controlled release of acetaminophen
loaded on the PVA−MNP ﬁbers, via an external magnetic ﬁeld.
Absolute ethanol was chosen as the medium for these
experiments, in which the magnetic ﬁbers were stable. UV−
vis experiments conducted on the supernatant of PVA−MNP
ﬁbers stored in absolute ethanol for 4 weeks showed no traces
of Fe3O4 leaching (Supporting Information Figure S2).
Acetaminophen was chosen as a model drug for this study
due to its high solubility in ethanol58 and its characteristic UV−
vis absorption.59 This drug was eﬀectively immobilized onto the
PVA−MNP ﬁbers (Figure 4A), following which the drug−ﬁber
system was transferred to an absolute ethanol medium and
studied for the release of acetaminophen with time, both with
and without magnetic actuation (Figure 4B,C and Supporting
Information Videos S2 and S3). Separate experiments were
conducted in duplicate, for the control (i.e., without actuation)
and actuated studies. Samples were taken out at relevant time
intervals and subject to UV−vis analysis. The ethanol volume
was kept constant for all samples throughout the study by
replacing the sampling volume.
Acetaminophen has strong UV absorption with a prominent
peak at 243 nm and a broad shoulder at around 290 nm, in
water.60 In absolute ethanol, these peaks were observed at 248
and 295 nm, respectively (Figure 5A). A calibration curve for
acetaminophen was obtained using standard solutions and was
used to determine the concentration of its quantities released
during the control and actuation experiments of the
acetaminophen-loaded ﬁber system. On the basis of the
above results, the concentration and the cumulative % of
acetaminophen released were plotted against time (Figures S4
and 5B, respectively).
It was evident that the magnetically actuated ﬁber system
released signiﬁcantly more acetaminophen with time, compared
to the nonactuated system. For the actuated samples, a rapid
release of acetaminophen was observed during the ﬁrst 5 min,
followed by a gradual increase, up to 15 min, following which
the release plateaued until the end of the experiment, at 30 min.
This behavior is consistent with a “burst-release” mechanism.61
About 50% of the drug was released within 2−3 min and over
90% by the end of 15 min of actuation. No statistically
signiﬁcant further increase in release concentration is observed
over the 15−30 min time frame. This may be because further
drug release is restricted due to the strong adsorption or
possible entrapment of remaining drug within the ﬁber matrix.
It is also noteworthy that, because the drug release is triggered
by movement (i.e., magnetic actuation), we are unable to
ensure that the acetaminophen concentration is homogeneous
throughout the test solution. This may result in greater
diﬀerences in duplicate experiments conducted for actuated
samples compared to the controls, bringing about larger
experimental errors for the former. In contrast, the control
samples released signiﬁcantly lower amounts of drug during the
ﬁrst 5 min, followed by a slower gradual increase in drug release
over the next 20 min, and ﬁnally showed a slight decrease
during the last 5 min. This behavior can be attributed to simple
Figure 3. Characterization of chemical composition and magnetic content of the PVA−MNP ﬁbers. (A) FTIR spectrum, (B) elemental analysis
using EDX, (C) area of ﬁber sample subject to EDX analysis, and (D) mass magnetization behavior of the MNP−PVA ﬁber sample.
Figure 4. Drug release experiments using magnetic ﬁbers. (A) Loading
of acetaminophen onto the ﬁbers, (B) control experiment without any
actuation, and (C) ﬁber−drug system actuated via an external magnet.
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diﬀusion of the immobilized acetaminophen from the ﬁber
network.
The diﬀerence between the cumulative % of acetaminophen
released over time from the actuated and nonactuated ﬁbers, for
the 5−30 min time frame, is depicted in Figure 5C. By the end
of the ﬁrst 5 min, there is a stark diﬀerence of about 71% of
acetaminophen release between the two types of samples. This
amounts to approximately 28 times higher drug release from
actuated ﬁbers compared to a nonactuated sample, as depicted
by the ratios in Figure 5D. This is followed by steadily
decreasing ratios of release up to 15 min, and by the end of the
30 min study period, about twice as much acetaminophen
continues to release via magnetic actuation, compared to
diﬀusion. The above is clear evidence that remote magnetic
actuation can bring about signiﬁcant changes in both an
absolute and a relative sense, for the release of drugs from
PVA−MNP ﬁbers.
On the basis of the above results, it is evident that the PVA−
MNP ﬁbers are capable of fast drug release during smaller time
scales and slower, consistent drug release over time, via
magnetic actuation. This novel, biocompatible, cost-eﬀective,
and controllable technique has the potential to be used
clinically, as an eﬀective tool for triggered drug release.
Application of this mode of drug delivery is particularly
attractive in wound care due to several reasons: (1) it can be
used in the community by tissue viability nurses, (2) repeated
drug delivery can be eﬀected, without necessarily changing or
removing the dressings, and (3) chemical debridement of
wounds (as opposed to surgical debridement for which one
needs an anesthetic, theater time, and, often, a physician to
conduct the procedure) can be carried out if the relevant drug
is incorporated into the PVA−MNP ﬁbers. Moreover, there is
increasingly a focus to move the management of wound care
into the community, which achieves two important NHS
objectives: (a) it relieves hospital bed pressures and (b)
patients can be managed in the convenience of their own
homes and are not subjected to the challenges of being an
inpatient.
This technology also has potential applications for “site-
speciﬁc” treatment due to its customizable properties. For
example, the sensitivity of magnetic actuation of the ﬁbers,
namely, the minimum depth and distance from the magnetic
source needed for actuation, can be improved by increasing
either the MNP concentration or the power of the magnet.
Then, the material can possibly be applied in treatment of
atherosclerotic plaque in the carotid artery or, in simpler terms,
for prevention of a stroke. In this instance, the magnetic ﬁbers
could be administered intravenously, and then the magnetic
actuation could be directed to the carotid artery in the neck so
that the drug would be released only at this speciﬁc site. If
deeper penetration of the magnetic force can be achieved safely,
then one could envisage widening the portfolio of use within
the body in a number of conditions, for example, acute
conditions such as sepsis and chronic diseases, such as
inﬂammation in arthritis and inﬂammatory bowel disease, and
in a range of oncological therapies.
4. CONCLUSIONS
PVA nanoﬁbers incorporating 5% (w/w) of magnetic Fe3O4
nanoparticles were successfully and reproducibly prepared by
infusion gyration. The ﬁbers were shown to be stable when
stored in ethanol, without any leaching of MNPs. The magnetic
particles impart suﬃcient magnetization to the ﬁbers to support
actuation via external magnets. Acetaminophen was used to
successfully demonstrate controlled drug release using the
PVA−MNP ﬁbers, when subject to magnetic actuation,
Figure 5. Use of magnetic ﬁbers for controlled release of acetaminophen with and without magnetic actuation. (A) Chemical structure and UV−vis
absorption spectrum of acetaminophen, (B) cumulative weight percentages of acetaminophen released with time. Here, the control experiment
represents the equivalent release of acetaminophen without magnetic (or any other type of) actuation. (C) Eﬀect of magnetic actuation on drug
release with time: the diﬀerence between actuated and nonactuated cumulative release curves. (D) Ratio of acetaminophen release from actuated and
nonactuated ﬁbers.
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bringing about over 90% cumulative release in 15 min.
Compared to nonactuated controls, the magnetic ﬁbers showed
approximately 71% more release of the drug within 5 min, in
absolute terms, and nearly 28 times higher release, in relative
terms. This is promising for applications of this technology as
an eﬃcient remote-controlled method for drug delivery. The
above, coupled together with facile, cost-eﬀective material
synthesis, with proven ability to scale up, oﬀers attractive
opportunities in clinical application of the magnetic ﬁbers.
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(39) Guimaraẽs, A.; Martins, A.; Pinho, E. D.; Faria, S.; Reis, R. L.;
Neves, N. M. Solving cell infiltration limitations of electrospun
nanofiber meshes for tissue engineering applications. Nanomedicine
2010, 5, 539−554.
(40) Martins, A.; Arauj́o, J. V.; Reis, R. L.; Neves, N. M. Electrospun
nanostructured scaffolds for tissue engineering applications. Nano-
medicine 2007, 2, 929−942.
(41) Zhang, Y.; Lim, C. T.; Ramakrishna, S.; Huang, Z.-M. Recent
development of polymer nanofibers for biomedical and biotechno-
logical applications. J. Mater. Sci.: Mater. Med. 2005, 16, 933−946.
(42) Zafar, M.; Najeeb, S.; Khurshid, Z.; Vazirzadeh, M.; Zohaib, S.;
Najeeb, B.; Sefat, F. Potential of Electrospun Nanofibers for
Biomedical and Dental Applications. Materials 2016, 9, 73.
(43) Tamimi, E.; Ardila, D. C.; Haskett, D. G.; Doetschman, T.;
Slepian, M. J.; Kellar, R. S.; Vande Geest, J. P. Biomechanical
Comparison of Glutaraldehyde-Crosslinked Gelatin Fibrinogen
Electrospun Scaffolds to Porcine Coronary Arteries. J. Biomech. Eng.
2015, 138, 011001.
(44) Tamayol, A.; Akbari, M.; Annabi, N.; Paul, A.; Khademhosseini,
A.; Juncker, D. Fiber-based tissue engineering: Progress, challenges,
and opportunities. Biotechnol. Adv. 2013, 31, 669−687.
(45) Gosline, J. M.; Guerette, P. A.; Ortlepp, C. S.; Savage, K. N. The
mechanical design of spider silks: from fibroin sequence to mechanical
function. J. Exp. Biol. 1999, 202, 3295−3303.
(46) Gomes, M. E.; Azevedo, H. S.; Moreira, A. R.; Ella,̈ V.;
Kellomak̈i, M.; Reis, R. L. Starch−poly(ε-caprolactone) and starch−
poly(lactic acid) fibre-mesh scaffolds for bone tissue engineering
applications: structure, mechanical properties and degradation
behaviour. J. Tissue Eng. Regener. Med. 2008, 2, 243−252.
(47) Sinclair, K. D.; Webb, K.; Brown, P. J. The effect of various
denier capillary channel polymer fibers on the alignment of NHDF
cells and type I collagen. J. Biomed. Mater. Res., Part A 2010, 95, 1194−
1202.
(48) Wan, A. C. A.; Liao, I.-C.; Yim, E. K. F.; Leong, K. W.
Mechanism of Fiber Formation by Interfacial Polyelectrolyte
Complexation. Macromolecules 2004, 37, 7019−7025.
(49) Mahalingam, S.; Edirisinghe, M. Forming of Polymer Nano-
fibers by a Pressurised Gyration Process. Macromol. Rapid Commun.
2013, 34, 1134−1139.
(50) Mahalingam, S.; Raimi-Abraham, B. T.; Craig, D. Q. M.;
Edirisinghe, M. Solubility−spinnability map and model for the
preparation of fibres of polyethylene (terephthalate) using gyration
and pressure. Chem. Eng. J. 2015, 280, 344−353.
(51) Illangakoon, U. E.; Mahalingam, S.; Wang, K.; Cheong, Y.-K.;
Canales, E.; Ren, G. G.; Cloutman-Green, E.; Edirisinghe, M.; Ciric, L.
Gyrospun antimicrobial nanoparticle loaded fibrous polymeric filters.
Mater. Sci. Eng., C 2017, 74, 315−324.
(52) Zhang, S.; Karaca, B. T.; VanOosten, S. K.; Yuca, E.;
Mahalingam, S.; Edirisinghe, M.; Tamerler, C. Coupling Infusion
and Gyration for the Nanoscale Assembly of Functional Polymer
Nanofibers Integrated with Genetically Engineered Proteins. Macro-
mol. Rapid Commun. 2015, 36, 1322−1328.
(53) Hong, X.; Edirisinghe, M.; Mahalingam, S. Beads, beaded-fibres
and fibres: Tailoring the morphology of poly(caprolactone) using
pressurised gyration. Mater. Sci. Eng., C 2016, 69, 1373−1382.
(54) Mallapragada, S. K.; Peppas, N. A. Dissolution mechanism of
semicrystalline poly(vinyl alcohol) in water. J. Polym. Sci., Part B:
Polym. Phys. 1996, 34, 1339−1346.
(55) Mansur, H. S.; Sadahira, C. M.; Souza, A. N.; Mansur, A. A. P.
FTIR spectroscopy characterization of poly (vinyl alcohol) hydrogel
with different hydrolysis degree and chemically crosslinked with
glutaraldehyde. Mater. Sci. Eng., C 2008, 28, 539−548.
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